Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Rudolph M Navari. (2017) Cancer patients at high risk for chemotherapy-induced nausea and vomiting – prediction assessments/tools. Expert Review of Quality of Life in Cancer Care 2:2, pages 103-108.
Read now
Read now
Piotr K Janicki. (2016) Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant–palonosetron combination. Therapeutics and Clinical Risk Management 12, pages 693-699.
Read now
Read now
Rudolph M. Navari. (2016) The safety and efficacy of NEPA (netupitant and palonosetron) in the treatment of chemotherapy-induced nausea and vomiting. Expert Review of Quality of Life in Cancer Care 1:4, pages 263-268.
Read now
Read now
Rudolph M. Navari. (2016) The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opinion on Drug Safety 15:3, pages 343-356.
Read now
Read now
Rudolph M Navari. (2015) Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Design, Development and Therapy 9, pages 155-161.
Read now
Read now
Rudolph M Navari. (2014) Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opinion on Pharmacotherapy 15:17, pages 2599-2608.
Read now
Read now
Articles from other publishers (17)
Rudolph M Navari, Jennifer Le-Rademacher, Fabrice Smieliauskas, Kathryn J Ruddy, Thomas James Saphner, Heshan Liu, Elizabeth Harlos, Adedayo A Onitilo, Karthik Giridhar, Preet Paul Singh, Pavan S Reddy, Selina Chow, Flavio Kruter, George Raptis & Charles L Loprinzi. (2023) Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602). The Oncologist 28:8, pages 722-729.
Crossref
Crossref
Raajeswari Satiamurthy, Nor Syafinaz Yaakob, Noraida Mohamed Shah, Norazrina Azmi & Marhanis Salihah Omar. (2023) Potential Roles of 5-HT3 Receptor Antagonists in Reducing Chemotherapy-induced Peripheral Neuropathy (CIPN). Current Molecular Medicine 23:4, pages 341-349.
Crossref
Crossref
Gaurav Kulkarni, Sireesha Murala & Pradeep C. Bollu. 2022. Neurochemistry in Clinical Practice. Neurochemistry in Clinical Practice
25
43
.
Ileana Slavin, Steven Dea, Priyanka Arunkumar, Neha Sodhi, Sandro Montefusco, Jair Siqueira-Neto, Janet Seelke, Mary Anne Lofstrom, Blake Anson, Fabian Zanella & Cassiano Carromeu. (2021) Human iPSC-Derived 2D and 3D Platforms for Rapidly Assessing Developmental, Functional, and Terminal Toxicities in Neural Cells. International Journal of Molecular Sciences 22:4, pages 1908.
Crossref
Crossref
Radomir Juza, Premysl Vlcek, Eva Mezeiova, Kamil Musilek, Ondrej Soukup & Jan Korabecny. (2020)
Recent advances with 5‐HT
3
modulators for neuropsychiatric and gastrointestinal disorders
. Medicinal Research Reviews 40:5, pages 1593-1678.
Crossref
Crossref
Muhammad Harith Zulkifli, Praveena Viswenaden, Malina Jasamai, Norazrina Azmi & Nor Syafinaz Yaakob. (2019) Potential roles of 5-HT3 receptor (5-HT3R) antagonists in modulating the effects of nicotine. Biomedicine & Pharmacotherapy 112, pages 108630.
Crossref
Crossref
Akihiko Osaki, Kenichi Inoue, Hiroshi Sakai, Kazuhiko Yamada, Koichi Minato, Fumiyoshi Ohyanagi, Yutaka Tokuda, Norihiko Ikeda, Hiroshi Kagamu, Kaoru Kubota, Tomohide Tamura & Toshiaki Saeki. (2019) A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy. Japanese Journal of Clinical Oncology 49:2, pages 121-129.
Crossref
Crossref
Sharon Rees. (2018) Drug therapies to manage nausea and vomiting. Nurse Prescribing 16:1, pages 37-44.
Crossref
Crossref
Nor Syafinaz Yaakob, Dan-Thanh Nguyen, Betty Exintaris & Helen Ruth Irving. (2018) The C and E subunits of the serotonin 5-HT3 receptor subtly modulate electrical properties of the receptor. Biomedicine & Pharmacotherapy 97, pages 1701-1709.
Crossref
Crossref
Rudolph M. Navari. (2017) Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients. Pediatric Drugs 19:3, pages 213-222.
Crossref
Crossref
Midori Nakagaki, Michael Barras, Cameron Curley, Jason P. Butler & Glen A. Kennedy. (2016) A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer 25:2, pages 607-613.
Crossref
Crossref
Qi Shi, Wen Li, Hongjia Li, Qiqi Le, Shanshan Liu, Shaoqi Zong, Leizhen Zheng & Fenggang Hou. (2016) Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison. Oncotarget 7:17, pages 24402-24414.
Crossref
Crossref
Rudolph M. Navari. 2016. Management of Chemotherapy-Induced Nausea and Vomiting. Management of Chemotherapy-Induced Nausea and Vomiting
107
120
.
Rudolph M. Navari. (2015) 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochimica et Biophysica Acta (BBA) - Biomembranes 1848:10, pages 2738-2746.
Crossref
Crossref
Rudolph M. Navari. (2015) Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting. BioMed Research International 2015, pages 1-6.
Crossref
Crossref
Rudolph M. Navari. 2015. International Manual of Oncology Practice. International Manual of Oncology Practice
779
804
.
Erin M. Rock, Cheryl L. Limebeer & Linda A. Parker. (2014) Anticipatory nausea in animal models: a review of potential novel therapeutic treatments. Experimental Brain Research 232:8, pages 2511-2534.
Crossref
Crossref